摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-丙基-2-嘧啶胺 | 45815-19-8

中文名称
N-丙基-2-嘧啶胺
中文别名
——
英文名称
N-propylpyrimidin-2-amine
英文别名
——
N-丙基-2-嘧啶胺化学式
CAS
45815-19-8
化学式
C7H11N3
mdl
MFCD11117652
分子量
137.184
InChiKey
CJYBMNVOWYJIOQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:d46dc3a599d70b00787e11108b9abf69
查看

反应信息

  • 作为反应物:
    描述:
    N-丙基-2-嘧啶胺正丁基锂 作用下, 以 正己烷 为溶剂, 反应 4.0h, 生成
    参考文献:
    名称:
    用于相变存储材料的氨基嘧啶Ge(Ⅱ)前质体 及其制备方法
    摘要:
    本发明涉及一种用于相变存储材料的氨基嘧啶Ge(II)前质体,该前质体以氨基嘧啶及其衍生物为配体,依以下方法制备:(1)将氨基密啶及其衍生物溶解在反应溶剂中,‑78~0℃搅拌条件下加入烷基锂溶液,氨基嘧啶或其衍生物与烷基锂摩尔比1.0∶1.0~1.2,恢复室温继续搅拌至固体产生,过滤得到锂盐;(2)将步骤(1)得到的锂盐与甲苯混合,‑78~0℃条件下以锂盐与金属锗摩尔比2.0∶1.0~1.2滴加到二氯化锗的甲苯溶液中,升温至室温;(3)将步骤(2)得到的混合物过滤浓缩,滤渣用二氯甲烷提取,收集滤液,‑50~0℃低温结晶,得到所述的氨基嘧啶Ge(II)前质体。本发明合成方法简单,制备的前质体热稳定性高,挥发性好,成膜性能优良,是制备相变存储材料潜在的重要前质体。
    公开号:
    CN104341355B
  • 作为产物:
    描述:
    2-amino-1-propylpyrimidin-1-ium iodidesodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 0.25h, 生成 N-丙基-2-嘧啶胺
    参考文献:
    名称:
    A Divergent Synthesis of Substituted 2-Aminoimidazoles from 2-Aminopyrimidines
    摘要:
    A new divergent and efficient synthesis of substituted 2-aminoimidazoles 5 and 6 has been developed starting from the readily available 2-aminopyrimidines 1 and alpha-broinocarbonyl compounds 2, Using conventional heating or microwave irradiation. Thus, the cleavage of 1,2,3-substituted imidazo[1,2-a]pyrimidin-1 -iumsalts 4 with hydrazine or secondary amines led to 1,4,5-trisubstituted 2-aminoimidazoles 5, when the hydrazinolysis of 2-hydroxy-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-4-ium salts 3, followed by a novel Dimroth-type rearrangement, resulted in formation of 2-amino-1H-imidazoles 6. The relevant pathway of transformations was identified by characterization of the intermediates.
    DOI:
    10.1021/jo8008758
点击查看最新优质反应信息

文献信息

  • A Facile Synthesis of Trifluoromethylamines by Oxidative Desulfurization–Fluorination of Dithiocarbamates
    作者:Kiyoshi Kanie、Katsuya Mizuno、Manabu Kuroboshi、Tamejiro Hiyama
    DOI:10.1246/bcsj.71.1973
    日期:1998.8
    conditions. When this reaction was applied to dithiocarbamates ArN(R)CS2Me at higher temperatures, the trifluoromethylation was accompanied by halogen substitution at the p-position of the Ar group. The synthesis of trifluoromethyl-substituted adenosine is also described.
    甲胺很容易从二氨基甲酸酯通过由四丁基二氢三氟化铵和 N-卤代酰亚胺组成的试剂系统在温和条件下合成。当该反应在较高温度下应用于二氨基甲酸酯 ArN(R)CS2Me 时,三甲基化伴随着 Ar 基团对位的卤素取代。还描述了三甲基取代的腺苷的合成。
  • Efficient One-Pot, Two-Step, Microwave-Assisted Procedure for the Synthesis of Polysubstituted 2-Aminoimidazoles
    作者:Denis S. Ermolat'ev、Eugene V. Babaev、Erik V. Van der Eycken
    DOI:10.1021/ol062421c
    日期:2006.12.1
    A microwave-assisted, one-pot, two-step protocol was developed for the construction of polysubstituted 2-aminoimidazoles. This process involves the sequential formation of imidazo[1,2-a]pyrimidinium salts from readily available 2-aminopyrimidines and alpha-bromocarbonyl compounds, followed by opening of the pyrimidine ring with hydrazine. [reaction: see text]
    开发了微波辅助的一锅两步操作规程,用于构建多取代的2-氨基咪唑。该过程涉及由容易获得的2-氨基嘧啶和α-羰基化合物顺序形成咪唑并[1,2-a]嘧啶鎓盐,然后用打开嘧啶环。[反应:看文字]
  • MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
    申请人:Marsault Eric
    公开号:US20100093720A1
    公开(公告)日:2010-04-15
    The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
    本发明提供了与胃动素受体及其亚型、异构体和/或变体结合和/或是功能调节剂的构象定义明确的大环化合物。这些大环化合物至少具有足够的药理特性,可用作治疗一系列疾病指示的治疗药物。特别是,这些化合物对于治疗和预防以高胃动素血症和/或胃肠道高蠕动性为特征的疾病非常有用,包括但不限于腹泻、癌症治疗相关腹泻、癌症诱导腹泻、化疗诱导腹泻、放射性肠炎、放射性腹泻、压力诱导腹泻、慢性腹泻、艾滋病相关腹泻、C. difficile相关腹泻、旅行者腹泻、移植物宿主病引起的腹泻、其他类型的腹泻、消化不良、肠易激综合征、化疗诱导的恶心和呕吐(呕吐)以及术后恶心和呕吐和功能性胃肠道疾病。此外,这些化合物对于治疗以胃或肠道吸收不良为特征的疾病和疾病也具有用途,例如短肠综合征、乳糜泻和虚弱。这些化合物还可用于治疗胃肠道炎症性疾病和疾病,如炎症性肠病、溃疡性结肠炎、克罗恩病和胰腺炎。因此,本发明还提供了治疗此类疾病的方法和包括本发明化合物的药物组合物。
  • Heterocyclic Compounds and Methods of Use
    申请人:Medivation Technologies LLC
    公开号:US20180051013A1
    公开(公告)日:2018-02-22
    This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    这份披露提供了化合物和使用这些化合物治疗代谢性疾病和增生性疾病的方法,包括与激素受体拮抗剂一起给予这些化合物的方法。
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    申请人:Medivation Technologies, Inc.
    公开号:US20150065519A1
    公开(公告)日:2015-03-05
    This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    本公开提供了化合物及其使用方法,用于治疗代谢性疾病和增生性疾病,包括与激素受体拮抗剂一起给予化合物的治疗方法。
查看更多